Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Lichen planopilaris LPP is a type of scarring hair loss caused by inflammation, leading to permanent hair loss and uncomfortable scalp symptoms like itching and burning. Current treatments often dont work well and can have side effects, so new targeted options are needed. Nemolizumab, a drug that blocks the IL-31 receptor and is approved for other itchy skin conditions, is being studied as a potential treatment for LPP in this phase 4 pilot study. Participants in the study will receive nemolizumab through subcutaneous injections every 4 weeks, with doses adjusted based on weight. This is a noncontrolled study, meaning all participants receive nemolizumab without comparison to a placebo or other treatment. The study will last at least 24 weeks, during which participants will be monitored for changes in their LPP symptoms. During the study, participants will have their hair loss and scalp condition assessed using specific scoring systems, including the Lichen Planopilaris Activity Index and the Investigator Global Assessment for scarring alopecia. They will also report on scalp itching using a numerical rating scale. Optional scalp biopsies may be performed for research. Safety and treatment effects will be followed over the 24-week period, with all assessments designed to understand how nemolizumab influences LPP activity and symptoms.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.
Actively Recruiting
Warts on the hands are common, non-cancerous skin growths caused by the human papillomavirus HPV. Treating warts in children can be difficult because common treatments like cryotherapy and injections are often not well tolerated. Existing creams have limited success and require long use. Researchers are studying tirbanibulin ointment as a possible effective and better-tolerated treatment for hand warts in children aged 8 to 18 years. Participants will apply tirbanibulin ointment 1% to the affected areas on their hands themselves. This study is open-label and involves one treatment group using only this topical medication. Treatment cycles will last up to four cycles, with participants applying the ointment as directed during the study period. During the study, children will be monitored for wart clearance two months after finishing treatment cycles. Assessments will include wart count and size, overall health status, and any side effects. The study will last through treatment and follow-up, ensuring safety and measuring how well the ointment works to clear warts on the hands.